NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Jun 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YEZTUGO (lenacapavir sodium) is a subcutaneous small-molecule solution approved by the FDA on June 18, 2025. It represents a novel therapeutic approach in a growth lifecycle stage, delivered via injection for chronic disease management. The drug's specific indication and mechanism of action are not disclosed in available data.
Growth14.2 years to LOE
Early-stage product in growth phase with emerging commercial infrastructure; teams are actively scaling go-to-market operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Gilead Sciences is hiring 3 roles related to this product
Worked on YEZTUGO at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.